A Phase 4 interventional study of Secukinumab 300 mg and Secukinumab 150 mg in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 58 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 13th largest by enrollment, is one of 5 that started in 2016, is one of 4 in phase 4, and was the 16th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 258 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 231 across the 26 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 26 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
31 studies in Arthritis, Psoriatic by Novartis: 3 open now, 3 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 31 studies in Arthritis, Psoriatic by Novartis, this one is the 13th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2016, is the only one in phase 4, and was the 15th registered.
Novartis’s Arthritis, Psoriatic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 31 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
Treatment Period 1 was defined as the period from Randomization through Week 16 (prior to the Week 16 dose). At the start of placebo-controlled Treatment Period 1, patients were randomized via Interactive Response Technology (IRT) in a 2:2:1 ratio to 1 of 3 treatment groups.
Group 1- Secukinumab 300 mg: secukinumab 300 mg (2 s.c. injections of the 150-mg dose) once weekly for 5 weeks (at Baseline, Weeks 1, 2, 3, and 4), followed by dosing every 4 weeks.
Group 2- Secukinumab 150 mg: secukinumab 150 mg (1 s.c. injection of the 150-mg dose and 1 s.c. injection of placebo) once weekly for 5 weeks (at Baseline, Weeks 1, 2, 3, and 4), followed by dosing every 4 weeks.
Group 3- Placebo: placebo (2 s.c. injections of 150 mg secukinumab placebo per dose) once per week for 5 weeks (at Baseline, Weeks 1, 2, 3, and 4), followed by dosing every 4 weeks.
At each study treatment visit 2 s.c. injections in the form of prefilled syringes (PFS) were administered. This was necessary to maintain the blind, as secukinumab in PFS is available in either 1.0 mL (150 mg) or 2 x 1.0 mL (300 mg). Placebo to secukinumab was also available in 1.0 mL to match the active drug.
Rescue medication was not allowed before completion of Week 16 assessments.
Treatment Period 2 patients receiving secukinumab 300 mg (Group 1) continued to receive the same dose up to Week 48.
At Weeks 16, 28, and 40 patients on secukinumab 150 mg (Group 2) were classified as responders (≥20% improvement from BL in both tender and swollen joint counts) or nonresponders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
secukinumab 300mg s.c. injection
Drug: Secukinumab 300 mg
secukinumab 150 mg s.c. injection
Drug: Secukinumab 150 mg
Placebo s.c. injection
Other: Placebo
150 mg x 2 s.c. injection
Also known as: AIN457
150 mg s.c. injection
Also known as: AIN457
Placebo
Also known as: s.c. injection
Percent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 16
A patient was considered as improved according to the ACR20 criteria if she/he had at least 20% improvement in two of the following measures:Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity, Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR). Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
Time frame: 16 Weeks
Percentage of Patients With Dactylitis in the Subset of Subjects Who Have Dactylitis at Week 16
The percent of patients in the Dactylitis Subset with dactylitis in the secukinumab 300 mg group at Week 16. Dactylitis is severe inflammation of the finger and toe joints. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
Time frame: Week 16
Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Baseline (SPARCC) at Week 16
Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
Time frame: 16 Weeks
Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (LEI)
Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. LEI=Leeds Enthesitis Index
Time frame: 16 Weeks
Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (Combined SPARCC and LEI)
Statistical analysis (logistic regression) of presence of enthesitis (Combined SPARCC and LEI) by visit - in treatment period 1 (non-responder imputation) (Combined SPARCC and LEI Subset) Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
Time frame: 16 Weeks
Percentage of Patients Achieving ACR50 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16
A patient was considered as improved according the ACR50 criteria if she/he had at least 50% improvement in the two of the following measures: Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity,Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR) Statistical analysis (logistic regression) of ACR50 response by visit - in treatment period 1 (non-responder imputation) (Full Analysis Set) Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
Time frame: 16 Weeks
Percentage of Patients Achieving ACR70 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16
A patient was considered as improved according the ACR70 criteria if she/he had at least 70% improvement in the two of the following measures: Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity,Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR) Statistical analysis (logistic regression) of ACR70 response by visit - in treatment period 1 (non-responder imputation) Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
Time frame: 16 Weeks
Percentage of Patients Achieving a PASI75 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16
A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis.
Time frame: 16 Weeks
Percentage of Patients Achieving a PASI90 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16
A 90% reduction in the Psoriasis Area and Severity Index score (PASI 90) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis.
Time frame: 16 Weeks
Percentage of Patients Achieving a PASI100 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16
A 100% reduction in the Psoriasis Area and Severity Index score (PASI 100) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
Time frame: 16 Weeks
Change From Baseline to Week 16 in DAS28-CRP
DAS-CRP uses the C-Reactive Protein (CRP) value. Disease Activity Score (DAS28-CRP) values range from 2.0 to 10.0 while higher values mean a higher disease activity. A DAS28-CRP below the value of 2.6 is interpreted as Remission. DAS28-CRP uses 28 different joints for its calculation: proximal interphalangeal joints (10 joints) metacarpophalangeal joints (10) wrists (2) elbows (2) shoulders (2) knees (2) With the above mentioned parameters. Least squares mean (LSM), Least squares mean (LSM) treatment difference, 95% confidence interval (CI) for treatment difference, and p-values are from an analysis of covariance (ANCOVA) model with treatment (3 treatment groups), baseline DAS28-CRP score, methotrexate usage at baseline (yes, no), and body weight(kg) as explanatory variables.
Time frame: baseline, 16 weeks
Change From Baseline to Week 16 in HAQ-DI
The Health assessment questionnaire disability index (HAQ-DI) is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).
Time frame: 16 Weeks
Number and Percentage of Patients With ACR20 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
Exploratory The ACR20 is a composite measure defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP)
Time frame: up to 52 weeks
Number and Percentage of Patients With ACR50, ACR70 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
Exploratory
Time frame: up to 52 weeks
Number and Percentage of Patients With Presence of Dactylitis by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
Exploratory
Time frame: up to 52 weeks
Number and Percentage of Patients With Presence of Enthesitis by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
Exploratory
Time frame: up to 52 weeks
Number and Percentage of Patients With Minimal Disease Activity Response by Visit in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
Exploratory
Time frame: up to 52 weeks
Number and Percentage of Patients With PASI75, PASI90 and PASI100 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
Exploratory
Time frame: up to 52 weeks
Of 349 patients screened for the study, 271 passed screening and 258 were randomized (103 to secukinumab 300 mg, 103 to secukinumab 150 mg, and 52 to placebo). A higher percentage of patients in the secukinumab 300 mg group completed Period 1 (94.2%) than in the secukinumab 150 mg (90.3%) or placebo (88.5%) groups.
| Milestone | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 |
|---|---|---|---|---|---|---|
| Started | 103 | 103 | 52 | 0 | 0 | 0 |
| Completed | 97 | 93 | 46 | 0 | 0 | 0 |
| Not completed | 6 | 10 | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal of informed consent | 2 | 7 | 3 | 0 | 0 | 0 |
| Milestone | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 |
|---|---|---|---|---|---|---|
| Started | 97 | 0 | 0 | 50 | 42 | 46 |
| Completed | 83 | 0 | 0 | 43 | 34 | 40 |
| Not completed | 14 | 0 | 0 | 7 | 8 | 6 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Adverse event | 5 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Technical problems | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal of informed consent | 1 | 0 | 0 | 2 | 2 | 3 |
A patient was considered as improved according to the ACR20 criteria if she/he had at least 20% improvement in two of the following measures:Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity, Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR). Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
| percentage of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 16 | 51.46 | 36.89 | 23.08 |
The percent of patients in the Dactylitis Subset with dactylitis in the secukinumab 300 mg group at Week 16. Dactylitis is severe inflammation of the finger and toe joints. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
| percent of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percentage of Patients With Dactylitis in the Subset of Subjects Who Have Dactylitis at Week 16 | 53.06 | 44.23 | 65.22 |
Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
| percentage of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Baseline (SPARCC) at Week 16 | 63.89 | 57.89 | 76.92 |
Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. LEI=Leeds Enthesitis Index
| percentage of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (LEI) | 56.06 | 52.24 | 82.35 |
Statistical analysis (logistic regression) of presence of enthesitis (Combined SPARCC and LEI) by visit - in treatment period 1 (non-responder imputation) (Combined SPARCC and LEI Subset) Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
| percentage of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (Combined SPARCC and LEI) | 62.16 | 59.21 | 82.05 |
A patient was considered as improved according the ACR50 criteria if she/he had at least 50% improvement in the two of the following measures: Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity,Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR) Statistical analysis (logistic regression) of ACR50 response by visit - in treatment period 1 (non-responder imputation) (Full Analysis Set) Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
| percentage of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percentage of Patients Achieving ACR50 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16 | 28.16 | 24.27 | 5.77 |
A patient was considered as improved according the ACR70 criteria if she/he had at least 70% improvement in the two of the following measures: Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity,Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR) Statistical analysis (logistic regression) of ACR70 response by visit - in treatment period 1 (non-responder imputation) Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
| percentage of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percentage of Patients Achieving ACR70 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16 | 17.48 | 10.68 | 1.92 |
A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis.
| percentage of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percentage of Patients Achieving a PASI75 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16 | 64.56 | 54.22 | 16.28 |
A 90% reduction in the Psoriasis Area and Severity Index score (PASI 90) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis.
| percentage of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percentage of Patients Achieving a PASI90 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16 | 49.37 | 36.14 | 9.3 |
A 100% reduction in the Psoriasis Area and Severity Index score (PASI 100) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.
| percentage of participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Percentage of Patients Achieving a PASI100 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16 | 25.32 | 18.07 | 2.33 |
DAS-CRP uses the C-Reactive Protein (CRP) value. Disease Activity Score (DAS28-CRP) values range from 2.0 to 10.0 while higher values mean a higher disease activity. A DAS28-CRP below the value of 2.6 is interpreted as Remission. DAS28-CRP uses 28 different joints for its calculation: proximal interphalangeal joints (10 joints) metacarpophalangeal joints (10) wrists (2) elbows (2) shoulders (2) knees (2) With the above mentioned parameters. Least squares mean (LSM), Least squares mean (LSM) treatment difference, 95% confidence interval (CI) for treatment difference, and p-values are from an analysis of covariance (ANCOVA) model with treatment (3 treatment groups), baseline DAS28-CRP score, methotrexate usage at baseline (yes, no), and body weight(kg) as explanatory variables.
| scores on a scale | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Change From Baseline to Week 16 in DAS28-CRP | -1.39 ± 0.120 | -1.18 ± 0.125 | -0.35 ± 0.170 |
The Health assessment questionnaire disability index (HAQ-DI) is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).
| scores on a scale | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Change From Baseline to Week 16 in HAQ-DI | -0.32 (-0.37 to -0.05) | -0.24 (-0.30 to 0.03) | -0.11 (NA to NA) |
Exploratory The ACR20 is a composite measure defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP)
| percentage of participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| week 1 | 17.48 | 8.00 | 4.76 | 5.83 | 1.92 |
| week 16 | 51.46 | 72.00 | 4.76 | 36.89 | 23.08 |
| week 52 | 47.57 | 68.00 | 28.57 | 44.66 | 42.31 |
Exploratory
| percentage of participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| ACR50 - week 1 | 2.91 | — | 2.38 | .97 | — |
| ACR50 - week 16 | 28.16 | 46.00 | 4.76 | 24.27 | 5.77 |
| ACR70 - week 16 | 17.48 | 22.00 | — | 10.68 | 1.92 |
| ACR50 - week 52 | 32.04 | 48.00 | 14.29 | 29.13 | 17.31 |
| ACR70 - week 52 | 21.36 | 28.00 | 4.76 | 15.53 | 5.77 |
Exploratory
| percentage of participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| week 1 | 42.72 | 42.00 | 35.71 | 40.78 | 32.69 |
| week 16 | 25.24 | 24.00 | 26.19 | 22.33 | 28.85 |
| week 52 | 10.68 | 6.00 | 11.90 | 7.77 | 9.62 |
Exploratory
| percentage of participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| week 1 | 84.85 | 66.67 | 88.89 | 77.61 | 79.41 |
| week 16 | 56.06 | 24.24 | 77.78 | 52.24 | 82.35 |
| week 52 | 53.03 | 36.36 | 66.67 | 53.73 | 61.76 |
Exploratory
| percentage of participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| week 1 | 0.97 | — | — | — | — |
| week 16 | 36.36 | 69.70 | 25.93 | 44.78 | 26.47 |
| week 52 | 26.21 | 42.00 | 14.29 | 26.21 | 3.85 |
Exploratory
| percentage of participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| PASI75 - week 1 | 8.86 | 7.5 | 11.76 | 8.43 | 4.65 |
| PASI90 - week 1 | 1.27 | — | 2.94 | 1.2 | 1 |
| PASI100 - week 1 | — | — | — | — | 2.33 |
| PASI75 - week 16 | 64.56 | 80.00 | 38.24 | 54.22 | 16.28 |
| PASI90 - week 16 | 49.37 | 60.00 | 17.65 | 36.14 | 9.30 |
| PASI100 - week 16 | 25.32 | 37.50 | — | 18.07 | 2.33 |
| PASI75 - week 52 | 67.09 | 77.50 | 52.94 | 59.04 | 53.49 |
| PASI90- week 52 | 48.10 | 67.50 | 35.29 | 46.99 | 44.19 |
| PASI100 - week 52 | 31.65 | 55.00 | 26.47 | 37.35 | 32.56 |
Collected over Adverse events (AE) were collected from first dose of study treatment until end of study treatment up to maximum duration of 52 weeks plus 12 weeks follow up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300mg | 0/191 (0%) | 15/191 (7.9%) | 66/191 (34.6%) |
| Secukinumab 150mg | 0/103 (0%) | 4/103 (3.9%) | 35/103 (34%) |
| Placebo | 1/52 (1.9%) | 3/52 (5.8%) | 12/52 (23.1%) |
| Event | Secukinumab 300mg | Secukinumab 150mg | Placebo |
|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/191 | 0/103 | 1/52 |
| Abdominal painGastrointestinal disorders | 0/191 | 0/103 | 1/52 |
| DiarrhoeaGastrointestinal disorders | 0/191 | 0/103 | 1/52 |
| Atypical pneumoniaInfections and infestations | 0/191 | 0/103 | 1/52 |
| Ischaemic strokeNervous system disorders | 0/191 | 0/103 | 1/52 |
| Myocardial infarctionCardiac disorders | 0/191 | 1/103 | 0/52 |
| Meningitis asepticInfections and infestations | 0/191 | 1/103 | 0/52 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/191 | 1/103 | 0/52 |
| SyncopeNervous system disorders | 1/191 | 1/103 | 0/52 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/191 | 1/103 | 0/52 |
| Event | Secukinumab 300mg | Secukinumab 150mg | Placebo |
|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 10/191 | 8/103 | 8/52 |
| Upper respiratory tract infectionInfections and infestations | 26/191 | 6/103 | 1/52 |
| SinusitisInfections and infestations | 8/191 | 3/103 | 4/52 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/191 | 3/103 | 4/52 |
| DiarrhoeaGastrointestinal disorders | 11/191 | 7/103 | 2/52 |
| NasopharyngitisInfections and infestations | 6/191 | 6/103 | 1/52 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 3/191 | 6/103 | 0/52 |
| HypertensionVascular disorders | 8/191 | 6/103 | 0/52 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 6/191 | 1/103 | 3/52 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/191 | 5/103 | 3/52 |
Randomized Set
| Age, Continuous(years) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Mean | 51.9 ± 12.56 | 51.3 ± 14.58 | 53.1 ± 12.67 | 52.2 ± 80.86 |
| Age, Customized(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| ≥18-<40 | 20 | 20 | 8 | 48 |
| ≥40-<65 | 65 | 61 | 35 | 161 |
| ≥65-<75 | 14 | 18 | 9 | 41 |
| ≥75 | 4 | 4 | 0 | 8 |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Female | 50 | 47 | 29 | 126 |
| Male | 53 | 56 | 23 | 132 |
| Race/Ethnicity, Customized(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Asian | 9 | 10 | 1 | 20 |
| Black | 2 | 2 | 3 | 7 |
| Caucasian | 88 | 88 | 45 | 221 |
| Native American | 0 | 1 | 1 | 2 |
| Other | 2 | 0 | 2 | 4 |
| Pacific Islander | 1 | 1 | 0 | 2 |
| Unknown | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jun 2016 to primary completion in Dec 2018, 29 months.
Results were first posted in Jan 2021, 2 years 1 month after primary completion. A results delay was requested in Oct 2019.
Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's 29 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab